Legend Biotech Co. (NASDAQ:LEGN) Shares Sold by National Pension Service

National Pension Service trimmed its position in shares of Legend Biotech Co. (NASDAQ:LEGN) by 5.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,258 shares of the company’s stock after selling 1,277 shares during the period. National Pension Service’s holdings in Legend Biotech were worth $724,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LEGN. Avior Wealth Management LLC raised its position in shares of Legend Biotech by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 11,097 shares of the company’s stock worth $541,000 after buying an additional 323 shares in the last quarter. Bridgewater Associates LP raised its position in shares of Legend Biotech by 0.3% during the 3rd quarter. Bridgewater Associates LP now owns 165,975 shares of the company’s stock worth $8,088,000 after buying an additional 516 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of Legend Biotech by 14.0% during the 3rd quarter. Advisors Asset Management Inc. now owns 6,812 shares of the company’s stock worth $332,000 after buying an additional 837 shares in the last quarter. Rhumbline Advisers raised its position in shares of Legend Biotech by 5.9% during the 4th quarter. Rhumbline Advisers now owns 27,638 shares of the company’s stock worth $899,000 after buying an additional 1,544 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Legend Biotech by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,320 shares of the company’s stock worth $564,000 after buying an additional 1,609 shares in the last quarter. 70.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on LEGN shares. Piper Sandler restated an “overweight” rating and set a $78.00 price target on shares of Legend Biotech in a research report on Monday, December 30th. Cantor Fitzgerald restated an “overweight” rating and set a $83.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a report on Tuesday, January 21st. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Legend Biotech currently has an average rating of “Buy” and an average price target of $79.50.

Legend Biotech Stock Performance

Legend Biotech stock opened at $35.01 on Friday. The firm’s 50 day simple moving average is $35.23 and its 200-day simple moving average is $42.32. The company has a market cap of $6.39 billion, a P/E ratio of -36.85 and a beta of 0.18. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. Legend Biotech Co. has a fifty-two week low of $30.17 and a fifty-two week high of $69.24.

Legend Biotech Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).